ChemicalBook >
제품 카탈로그 >Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]-
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]-
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- 구조식 이미지
카스 번호:
1132709-16-0
상품명:
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]-
동의어(영문):
Bortizomib SR-OH;(1S,2R)-BortezoMib;Bortezomib (1R,2R)Isomer;Bortezomib S,R Enantiomer;Bortezomib (1S, 2R)-Isomer;(1S,2R)-Bortezomib Impurity;Bortezomib S,R-Isomer Impurity;Bortezomib impurities (R, S-isomer);Bortezomib Impurity (1S,2R - Isomer);Bortezomib impurity 2/(1S,2R)-Bortezomib
CBNumber:
CB02677165
분자식:
C19H25BN4O4
포뮬러 무게:
384.24
MOL 파일:
1132709-16-0.mol
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- 속성
밀도
1.214±0.06 g/cm3(Predicted)
용해도
아세토니트릴(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
9.66±0.43(Predicted)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지
안정성
흡습성, 감광성, 수분 민감성
안전
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- C화학적 특성, 용도, 생산
용도
(1S,3R)-Bortezomib is an diastereomer of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- 준비 용품 및 원자재
원자재
준비 용품
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- 공급 업체
글로벌( 65)공급 업체
Canada 1
China 55
India 5
United States 4
Global 65
Boronic acid, B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]butyl]- 관련 검색:
2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-
BORTEZOMIB-PINANEDIOL
2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-
Bortezomib Impurity 2 (Mixture of (1S,2R)-Isomer and (1R,2R)-Isomer)
2-PyrazinecarboxaMide, N-[(1S)-2-[[(1S)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-
N-((S)-1-(((R)-1-Hydroxy-3-Methylbutyl)aMino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxaMide
Bortezomib Impurity 1 (R,S-Isomer)
BortezoMib IMpurity 2 (RR-IsoMer)
(S)-N-(1-(3-MethylbutanaMido)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxaMide
(S)-N-(1-AMino-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxaMide
bortezoMib iMpurity H
Bortezomib
((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid
(S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO] PROPANOIC ACID
(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate
((S)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid